Role of certain oral drugs in heavy menstrual bleeding.

Phase 2

• Conditions: Health Condition 1: N938- Other specified abnormal uterine and vaginal bleeding

• Registration Number: CTRI/2021/02/031090
• Lead Sponsor: ational Institute of Ayurveda

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: ot Yet Recruiting
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

1) Patients ready to participate in the clinical trial.

2) Patients diagnosed as dysfunctional uterine bleeding.

3) Excessive menstrual bleeding (amount >80 ml) or Prolonged menstrual bleeding ( >7 days) with or without heavy flow or Frequent menstrual cycle (interval < 21 days)

4) Patients presenting with inter-menstrual bleeding with or without heavy flow for 2 consecutive cycles.

Exclusion Criteria

1) Patients with chronic systemic illness (Congestive cardiac failure, Hypertension, cirrhosis of liver, Tuberculosis endometritis, severe anaemia, chronic renal disease, Insulin dependent diabetes mellitus etc.).

2) Patients using Intrauterine contraceptive device or oral contraceptive pills (Iatrogenic).

3) Patients with uterine and pelvic pathology (Fibroid size >2 cm, endometriosis, adenomyosis, polyp, high grade cervical erosion, endometrial thickness >20 mm etc.).

4) Congenital malformations of uterus(Septate uterus, double uterus).

5) Benign and malignant growth.

6) Thyroid dysfunction (endocrinal disorders).

7) Patients having bleeding due to abortion, ectopic pregnancy, during puerperium.

8) Patients taking Anti-coagulation therapy and having haematological disorders (Leukemia, Thrombocytopenic Purpura).

9) Postmenopausal bleeding.

10) Sexually transmitted infections/Genital tract infections.

Study & Design

• Study Type: Interventional
• Study Design: Not specified